PTPN12在不同分子分型乳腺癌组织中的表达及其与预后的关系

The PTPN12 expression in molecular subtypes of breast cancer

目的观察乳腺癌组织中PTPN12的表达情况,初步探讨其可能作用的蛋白,并分析其与临床病理参数及预后的关系。方法收集2005-2009年南方医院收治的84例乳腺癌患者的病理及临床资料,其中"三阴"乳腺癌患者50例,"非三阴"乳腺癌患者34例。采用免疫组化染色方法检测组织中PTPN12、EGFR的表达,并分析PTPN12表达与临床病理参数以及患者预后的关系。结果 "三阴"乳腺癌患者中PTPN12的缺失表达率、EGFR的阳性表达率显著高于"非三阴"乳腺癌患者(42.0%vs 20.6%,P=0.041;76.0%vs 47.1%,P=0.007)。PTPN12的表达与EGFR(rs=-0.208,P=0.058)、Her-2(rs=-0.250,P=0.022)存在负相关关系。PTPN12表达阴性的患者,其生存期更短。多因素分析表明PTPN12是乳腺癌独立的预后因子。结论PTPN12在"三阴"乳腺癌中具有更高的缺失突变,它的表达与EGFR和Her-2负相关。PTPN12是乳腺癌独立的预后因子。

Objective This study was to test the expression of PTPN12 in breast cancer,and to investigate the proteins potentially interacting with PTPN12.The association between PTPN12 and prognosis was also analyzed.Methods We collected 84 breast cancer samples and records between 2005 and 2009 in Nanfang hospital.50 cases of these were triple-negative breast cancers,34 cases were other types of breast cancers.Immunohistochemical staining technique was performed to measure the expression of PTPN12 and epidermal growth factor receptor EGFR.The correlations between PTPN12 expression and clinicopathological characteristics and prognosis were analyzed.Results Statistical analysis showed that the negative rate of PTPN12 was significantly higher in triple-negative breast cancer than that in other breast cancer（42.0% vs 20.6%,P=0.041）.The expression of EGFR was significantly higher in TNBC than in non-TNBC（76.0% vs 47.1%,P=0.007）.There was inverse correlation between EGFR expression and PTPN12（rs=-0.208,P=0.058）.PTPN12 expression showed significant correlation to human epidermal growth factor receptor-2（Her-2）（rs=-0.250,P=0.022）.Patients with negative PTPN12 expression had short overall survival.Multivariate analysis showed that PTPN12 was an independent prognostic indicator for patient survival.Conclusion Our results suggest that PTPN12 loss occurred frequently in triple-negative breast cancers.PTPN12 expression was negatively correlated to EGFR and Her-2.PTPN12 could be a prognosis factor in triple-negative breast cancer.